secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2026-01-02T23:59:59+00:00
Accession:  0001193125-26-000907
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara amends Pierre Fabre deal: cuts regulatory milestones by $9M, adds $15M commercial milestone
--------------------------------------------------------------------------------

- Regulatory milestone payments from Pierre Fabre reduced from $40M to $31M (decrease of $9M).
- New $15M commercial milestone payable upon Product Net Sales exceeding a confidential threshold.
- Amendment also modifies other payment sections (redacted) in the commercialization agreement.
- Atara submitted BLA for tab-cel (EBV+ PTLD) to FDA in May 2024; Pierre Fabre has exclusive U.S. commercialization rights.
- Agreement originally dated October 2023; fourth amendment effective December 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526000907/0001193125-26-000907-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526000907/d90230d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-000907

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer